BridgeBio Dividend Yield from 2010 to 2025

BBIO Stock  USD 32.97  0.66  2.04%   
BridgeBio Pharma Dividend Yield yearly trend continues to be very stable with very little volatility. Dividend Yield is likely to grow to 0.0004 this year. Dividend Yield is a financial ratio that shows how much BridgeBio Pharma pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share. View All Fundamentals
 
Dividend Yield  
First Reported
2010-12-31
Previous Quarter
0.000311
Current Value
0.000398
Quarterly Volatility
0.00008864
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BridgeBio Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Pharma's main balance sheet or income statement drivers, such as Interest Income of 18.1 M, Depreciation And Amortization of 6.4 M or Interest Expense of 104.3 M, as well as many indicators such as Price To Sales Ratio of 21.86, Dividend Yield of 4.0E-4 or Days Sales Outstanding of 7.38. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Pharma Valuation or Volatility modules.
  
Check out the analysis of BridgeBio Pharma Correlation against competitors.
To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

Latest BridgeBio Pharma's Dividend Yield Growth Pattern

Below is the plot of the Dividend Yield of BridgeBio Pharma over the last few years. Dividend Yield is BridgeBio Pharma dividend as a percentage of BridgeBio Pharma stock price. BridgeBio Pharma dividend yield is a measure of BridgeBio Pharma stock productivity, which can be interpreted as interest rate earned on an BridgeBio Pharma investment. It is a financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share. BridgeBio Pharma's Dividend Yield historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Pharma's overall financial position and show how it may be relating to other accounts over time.
Dividend Yield10 Years Trend
Slightly volatile
   Dividend Yield   
       Timeline  

BridgeBio Dividend Yield Regression Statistics

Arithmetic Mean0.0004
Geometric Mean0.0004
Coefficient Of Variation23.82
Mean Deviation0.000084
Median0.0005
Standard Deviation0.000089
Sample Variance0.00000001
Range2.0E-4
R-Value(0.73)
Mean Square Error0
R-Squared0.53
Significance0
Slope(0.000014)
Total Sum of Squares0.00000012

BridgeBio Dividend Yield History

2025 3.98E-4
2024 3.11E-4
2018 2.71E-4

About BridgeBio Pharma Financial Statements

BridgeBio Pharma investors utilize fundamental indicators, such as Dividend Yield, to predict how BridgeBio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock:
Check out the analysis of BridgeBio Pharma Correlation against competitors.
To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.88)
Revenue Per Share
1.193
Quarterly Revenue Growth
2.371
Return On Assets
(0.48)
Return On Equity
(17.90)
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.